B+
Bull case
30%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
TNDM
Tandem Diabetes CareANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Q2 sales increased 6% to $254.6 million, gross margin expanded 460 basis points to 57%, adjusted EBITDA turned positive, and international pump shipments grew strongly. Mobi tubeless clearance, broader sensor compatibility, pharmacy access, and international launches offer multiple ways to accelerate growth.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +15.3.
What can break
Competition from established and emerging automated insulin-delivery systems could limit adoption or pricing power.
Momentum
73
Value
37
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $23.00 · Bull $30.00 · Bear $12.00Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $29.16
Why
Momentum73 · Δ7d -10.1
Value37 · Δ7d -0.0
Sentiment100 · Δ7d +15.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +15.3.
Contradictions & invalidation
- • Competition from established and emerging automated insulin-delivery systems could limit adoption or pricing power.
- • FDA clearance or commercialization of Mobi tubeless could be delayed, reducing the principal near-term product catalyst.
- • U.S.
Catalyst clock
2026-11-15
Pharmacy-channel adoption and U.S. pump momentum
Lead driver: Sentiment · See AI snapshot
Momentum
73
9% active weight
Current posture
7d trendSoftening
Δ7d
-10.1
Δ21d
-23.8
Value
37
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.2
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+15.3
Δ21d
+33.8
Why this grade
Composite grade A. Momentum 73.0 / Value 36.6 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$23.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.55B
Beta
1.69
Shares Out
69.58M
P/E (TTM) · Derived
-7.3
P/S (TTM)
1.56
P/FCF (TTM) · Derived
-58.08
Rev YoY
+5.6%
EPS YoY
-60.8%
Gross Margin
+56.0%
Op Margin
-4.2%
Net Debt
$156.71M
Current Ratio
3.18
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data